Compare COOK & MXCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | COOK | MXCT |
|---|---|---|
| Founded | 1985 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Wholesale Distributors | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 83.7M | 86.5M |
| IPO Year | 2021 | 2021 |
| Metric | COOK | MXCT |
|---|---|---|
| Price | $28.17 | $0.75 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 5 | 4 |
| Target Price | ★ $58.00 | $7.50 |
| AVG Volume (30 Days) | 535.0K | ★ 976.9K |
| Earning Date | 03-05-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $559,520,000.00 | $38,627,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $5.50 | $9.64 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.48 | $0.64 |
| 52 Week High | $35.56 | $3.17 |
| Indicator | COOK | MXCT |
|---|---|---|
| Relative Strength Index (RSI) | 79.73 | 39.00 |
| Support Level | $0.98 | $0.75 |
| Resistance Level | N/A | $0.87 |
| Average True Range (ATR) | 1.45 | 0.06 |
| MACD | 3.40 | 0.01 |
| Stochastic Oscillator | 77.71 | 13.19 |
Traeger Inc designs, sources, sells, and supports wood pellet fueled barbeque grills sold to retailers, distributors, and direct to consumers. It produces and sells the pellets used to fire the grills and also sells Traeger-branded rubs, spices, and sauces, as well as grilling accessories including covers, barbeque tools, trays, liners, and merchandise. The company's geographical segments include North America and the Rest of the world, of which majority of revenue is from North America.
MaxCyte Inc is a commercial cell engineering company focused on providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics and to support cell-based research and development. The company has developed and commercialized a proprietary Flow Electroporation platform, which facilitates the complex engineering of a wide variety of cells. The Company has one reportable segment, cell engineering technology. The revenue is generated from the sale and licensing of company's instruments, as well as sales of single-use disposable processing assemblies.